Bortezomib (velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 1, 2012, Pages 26-31

  Nabhan, Chadi ^a   Villines, Dana ^a   Dalal, Neil ^a   Tolzien, Kathy ^a   Kozolff, Mark ^b   Starr, Alexander ^b  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b Monroe Medical Associates   (United States)

Author keywords

Chemoimmunotherapy; Low grade lymphoma; Rituximab; Velcade

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; RITUXIMAB;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOXICITY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; MANTLE CELL LYMPHOMA; MYELITIS; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; REVIEW; TRANSPLANTATION; VASCULITIS;

EID: 84856846498     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.05.040     Document Type: Article

References (19)

1. R.I. Fisher, M. LeBlanc, O.W. Press, D.G. Maloney, J.M. Unger, T.P. Miller New treatment options have changed the survival of patients with follicular lymphoma J Clin Oncol 23 2005 8447 8452
2. W. Hiddemann, M. Kneba, M. Dreyling Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 106 2005 3725 3732 (Pubitemid 41742196)
3. R. Marcus, K. Imrie, P. Solal-Celigny Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma J Clin Oncol 26 2008 4579 4586
4. A.D. Zelenetz, J.S. Abramson, R.H. Advani NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas J Natl Compr Canc Netw 8 2010 288 334
5. O.A. O'Connor, J. Wright, C. Moskowitz Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 2005 676 684 (Pubitemid 46237441)
6. D.E. Reece, G.P. Rodriguez, C. Chen Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma J Clin Oncol 26 2008 4777 4783
7. C.B. Reeder, D.E. Reece, V. Kukreti Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial Leukemia 23 2009 1337 1341
8. S. Bringhen, A. Larocca, D. Rossi Efficacy and safety of once-weekly bortezomib in multiple myeloma patients Blood 116 2010 4745 4753
9. I.M. Ghobrial, F. Hong, S. Padmanabhan Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia J Clin Oncol 28 2010 1422 1428
10. B.D. Cheson, S.J. Horning, B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
11. M.S. Czuczman, R. Weaver, B. Alkuzweny, J. Berlfein, A.J. Grillo-Lopez Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol 22 2004 4711 4716
12. M. Rummel, N. Niederle, G. Maschmeyer Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) Blood 2009 114
13. M. Wang, X.H. Han, L. Zhang Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo Leukemia 22 2008 179 185
14. S. de Vos, A. Goy, S.R. Dakhil Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma J Clin Oncol 27 2009 5023 5030
15. A. Agathocleous, A. Rohatiner, S. Rule Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia Br J Haematol 151 2010 346 353
16. R.A. Baiocchi, L. Alinari, M.E. Lustberg et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma Cancer 2010 [Epub ahead of print]
17. J.W. Friedberg, J.M. Vose, J.L. Kelly The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Blood 117 2011 2807 2812
18. J.F. Gerecitano, C. Portlock, P.A. Hamlin Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma Clin Cancer Res 17 2011 2493 2501
19. S.P. Treon, L. Ioakimidis, J.D. Soumerai Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 J Clin Oncol 27 2009 3830 3835